AUTHORS
Emily Tsai, Vineet Polineni, DO2, Tara Rakiewicz, MD3, Amy Shaver, PhD, PharmD, MPH4, Kuang-Yi Wen, PhD5, Chetan Jeurkar, DO6, Gina Keiffer, MD7, Margaret Kasner, MD8, Lindsay Wilde, MD9
AFFILIATIONS
1 Thomas Jefferson University Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania, United States, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
2 Jefferson University Hospital Jefferson Stratford Hospital, Stratford, New Jersey, United States
3 Thomas Jefferson University Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania, United States
4 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
5 Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
6 Thomas Jefferson University Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania, United States
7 Thomas Jefferson University Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania, United States
8 Thomas Jefferson University Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania, United States
9 Thomas Jefferson University Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania, United States
ABSTRACT
Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm defined by the presence of the Philadelphia chromosome, which arises from the reciprocal t(9;22) translocation [1]. Prior to the development of oral tyrosine kinase inhibitors (TKIs), CML was treated with interferon-based regimens and allogeneic stem cell transplant (SCT) [1]. TKIs have been the mainstay of treatment since imatinib’s FDA approval in May 2001 [2]. This breakthrough led to a dramatic improvement in the survival of patients with CML, now with life expectancy approaching that of the general population [3, 4]. After imatinib, multiple TKIs have been developed for CML treatment, including dasatinib, nilotinib, bosutinib, asciminib, and ponatinib. While all very effective, each TKI is unique in its side effect profile, dosing, drug-drug interactions, and cost. Choice of first-line treatment and sequence of subsequent treatments varies. We aimed to evaluate TKI prescribing patterns for patients across multiple populations.
Methods: We conducted a retrospective cohort study using de-identified electronic health record data from Epic Cosmos, a national database representing multiple U.S. health systems. The study included adults diagnosed with CML between January 2015 and June 2026. Patients were eligible if they had a diagnosis of CML and initiated TKI on or after the date of diagnosis. Index therapy was defined as the first TKI initiated following CML diagnosis. Patients with prior SCT or chemotherapy before index were excluded. Lines of therapy (LoT) were constructed longitudinally based on sequential use of distinct TKIs, with transition from first-line (1L) to second-line (2L) defined by initiation of a different TKI. Descriptive statistics were used to summarize baseline characteristics and treatment patterns. Kaplan–Meier methods were used to estimate time to treatment discontinuation.
Results: A total of 36,341 patients were included in the analytic cohort. The proportion of Non-Hispanic Black (NHB) patients decreased with increasing age, from 15.3% among patients under 50 years to 7.1% among patients aged 75 years or older. Younger patients were more likely to receive dasatinib as index therapy (48.6% among patients under 50 years), whereas older patients were increasingly treated with imatinib, rising from 30.0% among patients under 50 years to 51.8% among patients aged 75 years or older. Differences in prescribing patterns by Rural Urban Commuting Area (RUCA) classification were modest. Imatinib use was similar in rural and urban areas (40.0% vs. 39.3%), while dasatinib was slightly more common in urban compared with rural areas (37.8% vs. 36.1%). Prescribing patterns were broadly consistent across Social Vulnerability Index (SVI) categories, with imatinib use ranging from 38.5% to 41.4% and dasatinib use ranging from 36.9% to 38.4%. Small increases in later-generation TKIs, particularly bosutinib and ponatinib, were observed among patients with higher social vulnerability. Overall, 35.5% of patients experienced treatment discontinuation, 35.0% underwent switching, 60.0% experienced treatment interruption, and 23.9% had dose reductions. Treatment modification rates varied by index TKI: discontinuation was highest among patients receiving ponatinib and dasatinib (43.2% and 40.9%, respectively), and lowest among those receiving asciminib (18.2%). Treatment modification rates decreased with increasing age. Discontinuation was highest among patients under 50 years (40.0%) and lowest among those aged 75 years or older (30.0%); similarly, interruption decreased from 64.1% in patients under 50 years to 52.1% in patients aged 75 years or older.
Conclusions: These results highlight that younger age groups demonstrated a higher proportion of NHB and other racial/ethnic minority populations of patients with CML than older age groups. Older patients were prescribed imatinib more frequently than later generation TKIs, and younger patients were more likely to switch TKIs. Asciminib was associated with the lowest discontinuation rate, although this is likely related to asciminib being the most recently approved drug with the shortest amount of follow-up. Further investigation to evaluate the incidence of and potential risk factors for CML in different racial ethnic groups is needed.
DISCLOSURES
Emily Tsai: No relevant conflicts of interest to declare.